Crombez Eric 4

What Happened
Eric Crombez, Executive Vice President and Chief Medical Officer of Ultragenyx Pharmaceutical (RARE), received equity awards on April 16, 2026. The filing reports two awards totaling 94,626 shares: 34,674 shares acquired as an award and 59,952 shares reported as a derivative award (both at $0.00 acquisition price). These are restricted stock unit (RSU) grants (compensation awards), not open-market purchases or sales.

Key Details

• Transaction date: 2026-04-16; Form 4 filed 2026-04-20 (filed timely).
• Awards: 34,674 RSUs (A) and 59,952 RSUs (derivative A), total 94,626 RSUs; acquisition price reported $0.00.
• Vesting: RSUs vest 1/4 on each anniversary of the grant and fully vest on the fourth anniversary (see footnote F1).
• Shares owned after transaction: not specified in this Form 4; filing notes inclusion of previously reported RSUs (footnote F2).
• Footnotes: F1 describes the 4-year annual RSU vesting; F2 notes inclusion of previously reported RSU shares; F3 describes a standard option vesting schedule (appears to be boilerplate and not the subject of the current RSU awards).
• Filing timeliness: Report appears timely (filed within required SEC window).

Context
These awards are standard equity compensation used to retain executives; they are not purchases or sales and do not represent an immediate cash investment or divestiture. The derivative designation indicates the awards are stock-settled units that will convert into common shares as they vest.